Tada....I know its Bear's question, but this might help:

https://www.resverlogix.com/upload/media_element/250/01/rd-day-october-2016---sweeney.pdf

That's their Oct 2016 presentation which outlines how many people enrolled in each trial and how many have been dosed with Apabetalone....

706 received treatment with apabetalone including 576 patients with CAD and/or dyslipidemia on top of standard of care therapy • Three Phase 2 studies in patients with CAD have been completed: – 12-week (ASSERT) enrolled 299 patients – 24-week (SUSTAIN) enrolled 176 patients – 26-week (ASSURE) enrolled 323 patients • On going Phase 3 CVOT (BETonMACE) is currently ~1/3 enrolled